Cough Suppressant Drugs Market Analysis | CMI

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
COUGH SUPPRESSANT DRUGS MARKET ANALYSIS

• Cough Suppressant Drugs Market, by Disease Type
  (Dry Cough and Wet Cough), by Drug Type
  (Dextromethorphan, Codeine, Noscapine,
  Butamirate, Benzonatate, Pholcodine, and Others),
  by Product Type (Over-the-counter (OTC) and
  Prescription Drug), by Age Group (Pediatric and
  Adult), by Dosage Form (Syrup, Tablet, and
  Others), by Distribution Channel (Hospital,
  Retail Pharmacy, Online Pharmacy, and Others),
  and Region (North America, Latin America, Europe,
  Asia Pacific, Middle East, and Africa) - Size,
  Share, Outlook, and Opportunity Analysis, 2018
  2026
• The global cough suppressant drugs market size
  was valued at US 1100.4 Mn in 2017 and is
  expected to witness a CAGR of 3.7 during the
  forecast period (2018 2026).

3
Market Drivers

• Frequent approvals and launch of new cough
  suppressant drugs and high prevalence of cough is
  expected to drive the market growth
• In March 2018, Perrigo Company plc. received the
  FDA approval for the brand OTC equivalent of
  Mucinex DM Maximum Strength (Guaifenesin and
  Dextromethorphan Hydrobromide Extended-release
  Tablets, 1200 mg/60 mg). Mucinex DM Maximum
  Strength is indicated to control coughs and to
  break up mucus, making coughs more productive.
  Approval and launch of such new drugs in the
  market is expected to drive the Cough Suppressant
  Drugs Market growth over the forecast period.
• High prevalence of cough is also expected to be a
  major factor for rising demand for cough
  suppressant drugs, which drives the market
  growth. For instance, according to the data
  published by the National Center for
  Biotechnology Information in 2014, cough is the
  most common reason for visits to primary care
  physicians globally, accounting for around 8 of
  all consultations. According to the same source,
  the annual prevalence of cough in the general
  population is reported as approximately 1033
  globally.

4
Statistics

• North America is expected to hold dominant
  position, owing to frequent approvals of new
  cough suppressant drugs by FDA
• North America cough suppressant market is
  expected to show good growth over the forecast
  period, owing to frequent approvals to novel
  drugs by the FDA. For instance, in 2015, Vernalis
  plc and Tris Pharma Inc. received the U.S. Food
  and Drug Administration (FDA) approval for the
  New Drug Application (NDA) for Tuzistra XR
  (codeine polistirex and chlorpheniramine
  polistirex) extended-release oral suspension,
  CIII (DEA Schedule III). Tuzistra XR is a
  codeine-based extended-release oral suspension
  for cough-cold treatment.

5
Figure 1. Global Cough Suppressant Drugs Market
Share () Analysis, By Region, 2026
6
Key Development

• Key players in the market are involved in
  strategic mergers and partnerships, in order to
  develop, manufacture, and sell novel cough
  suppressant drugs and to gain major market share.
• For instance, in 2015, Tris Pharma, Inc. entered
  into a license, supply, and distribution
  agreement with Pfizer Consumer Healthcare (a part
  of Pfizer Inc.). According to the agreement,
  Pfizer Consumer Healthcare will commercialize
  Tris extended release dextromethorphan cough
  syrup under the Robitussin Brand. In exchange,
  Tris will provide the U.S. branded rights to its
  protected intellectual property for an extended
  release dextromethorphan formulation to Pfizer
  Consumer Healthcare and Tris will receive an
  upfront payment, milestone payments, and
  sales-based royalties.

7
Figure 2. Global Cough Suppressant Drugs Market
Share () Analysis, By Distribution Channel, 2026
8
Market Opportunities

• Various new players are entering lucrative cough
  suppressant drugs market by partnering with other
  manufacturers. For instance, in November 2018,
  Aytu BioScience, Inc., a specialty pharmaceutical
  company, entered into the cough suppressant drugs
  market with an exclusive license of FDA-approved
  Tuzistra XR from Tris Pharma Inc. Along with
  Tuzistra XR, Aytu BioScience, Inc. also has a
  licensed complementary antitussive product with
  pending FDA approval.

9
Market Restraints

• However, stringent regulations against the use of
  cough suppressant is expected to affect the
  global cough suppressant drugs market growth over
  the forecast period.
• For instance, in February 2018, the Therapeutic
  Goods Administration reclassified codeine as
  prescription only medicine in Australia, which
  was previously available as over-the-counter
  medication. This reclassification was made, as
  regular use of medicines containing codeine may
  lead to its addiction.
• In January 2018, the U.S. Food and Drug
  Administration made safety labeling changes to
  limit the use of codeine or hydrocodone
  containing prescription opioid cough and cold
  medicines in children younger than 18 years old
  to protect kids from serious risks of opioid
  ingredients containing cough treatment drugs.
  After the safety labeling changes, these products
  will no longer be indicated for treatment of
  cough in pediatric population and will be labeled
  for use only in adults aged 18 years and older.

10
Key Players

• Key players operating in the global cough
  suppressant drugs market include Perrigo Company
  plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc.,
  Aytu BioScience, Inc., Acella Pharmaceuticals
  LLC, Mayne Pharma Inc., Taro Pharmaceutical
  Industries Ltd., Amneal Pharmaceuticals LLC,
  Aurobindo Pharma Ltd, and GlaxoSmithKline plc.

11

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference https//www.coherentmarketinsights.com
  /market-insight/cough-suppressant-drugs-market-242
  7

12
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

13
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

14

• Thank You!
• Kindly follow CMI Social Media Profiles
  for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/